BiotechTube

Ruxolitinib + BAT

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Polycythemia Vera (PV)

Conditions

Polycythemia Vera (PV), Essential Thrombocythemia (ET)

Trial Timeline

Oct 1, 2015 → Dec 1, 2028

NCT ID
NCT02577926

About Ruxolitinib + BAT

Ruxolitinib + BAT is a phase 2 stage product being developed by Novartis for Polycythemia Vera (PV). The current trial status is active. This product is registered under clinical trial identifier NCT02577926. Target conditions include Polycythemia Vera (PV), Essential Thrombocythemia (ET).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02577926Phase 2Active

Competing Products

20 competing products in Polycythemia Vera (PV)

See all competitors
ProductCompanyStageHype Score
Sapablursen + PlaceboOno PharmaceuticalPhase 3
77
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
BomedemstatMerckPhase 2
52
Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3
77
ruxolitinib tabletsNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
RuxolitinibNovartisPhase 3
77
HydroxyureaNovartisApproved
85
Best Available Therapy + RuxolitinibNovartisPhase 3
77
Smac Mimetic LCL161NovartisPhase 2
52
PEGASYS + AspirinRochePhase 2
52
RG7388 + PegasysRochePhase 1
33
IdasanutlinRochePhase 2
52
PEGASYS + Hydroxyurea + AspirinRochePhase 3
77
Ropeginterferon alfa-2bPharmaEssentiaPhase 2
51
Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPharmaEssentiaPhase 3
76
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)PharmaEssentiaPhase 3
76
Ropeginterferon alfa-2bPharmaEssentiaApproved
84
P1101 + Low-dose aspirinPharmaEssentiaPhase 2
51
P1101 (Ropeginterferon alfa-2b)PharmaEssentiaPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85